Neurotec Pharma | Date: 2011-01-04
The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburgs acute M S, Balss concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO).
Dr Pablo Villoslada Chief of Neuroimmunology Group, Hospital Clnic-IDIBPAS, Barcelona, Spain. Dr Xavier Montalban Director of the Multiple Sclerosis Center of Catalonia (CEMCat), Clinic Neuroimmunology Unit, Hospital Universitari Vall dHebron, Barcelona, Spain Dr Rafael Arroyo Chief of Multiple Sclerosis Unit, Neurology Service, Hospital Clnico San Carlos, Madrid, Spain ...
NT-KO-003: Clinical Phase IIa in Relapsing/Remitting Multiple Sclerosis (RR-MS) NT-KO-003 film coated tablets is a novel oral product for the treatment of multiple sclerosis. NT-KO-003 has shown encouraging results in an accepted Multiple Sclerosis (MS) animal model both in pre-treatment and post-treatment study designs ...
Neurotec Pharma | Date: 2011-08-16
The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis.